Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth

Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administ...

Full description

Saved in:
Bibliographic Details
Published in:Oxidative medicine and cellular longevity 2018-01, Vol.2018 (2018), p.1-8
Main Authors: Banach, Maciej, Horzelski, Wojciech, Oszukowski, Przemysław, Suliburska, Joanna, Kocyłowski, Rafał, Gaj, Zuzanna, Grzesiak, Mariusz, von Kaisenberg, C.
Format: Article
Language:English
Subjects:
Analysis
Antioxidants
Biomarkers
Blood proteins
Clinical Study
Drug dosages
Endocrinology
Enzyme-linked immunosorbent assay
Ethylenediaminetetraacetic acid
Gynecology
Hospitals
Infants (Premature)
Mortality
Obstetrics
Oxidative stress
Poland
Pregnancy
Pregnancy complications
Pregnant women
Premature birth
Proteins
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663
cites cdi_FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663
container_end_page 8
container_issue 2018
container_start_page 1
container_title Oxidative medicine and cellular longevity
container_volume 2018
creator Banach, Maciej
Horzelski, Wojciech
Oszukowski, Przemysław
Suliburska, Joanna
Kocyłowski, Rafał
Gaj, Zuzanna
Grzesiak, Mariusz
von Kaisenberg, C.
description Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administration of the tocolytic drug Atosiban—a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm birth and its impact on the level of oxidative stress in pregnant women after 48 hours of tocolytic treatment. This prospective study was conducted between March 2016 and August 2017 at the Obstetric Clinic of the Polish Mother’s Memorial Hospital Research Institute. Total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl, and thiol group levels were measured using an ELISA test in serum and plasma of 56 pregnant women before and after 48 hours of continuous administration of Atosiban. We found that TAS levels decreased almost twice after the 48-hour drug administration (0.936 ± 0.360 mmol/L vs. 0.582 ± 0.305 mmol/L, P
doi_str_mv 10.1155/2018/3919106
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6304866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A602717127</galeid><sourcerecordid>A602717127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663</originalsourceid><addsrcrecordid>eNqN0c1rFDEYBvBBFPuhN88S8CLo2nxMMpOLsBY_ioUKLngMmeTNbspMsibZ1v73Zt11q548JZAfT96Xp2meEfyGEM7PKCb9GZNEEiweNMdEtnSGpWwfHu4YHzUnOV9jLBhtyePmiGFBqRDdcfP56oe3uvgbQF9LgpyRD-hbnCCgRQJdwKJbX1ZoXmL2gw7IxYQupjUE68MSfUlQIE3onU9l9aR55PSY4en-PG0WH94vzj_NLq8-XpzPL2emlbLMGOuAuIGYlgvcOcMH1zLGbScGzcDaFozrpeaWG9CG2A7awQkiATrSCcFOm7e72PVmmMAaCCXpUa2Tn3S6U1F79fdL8Cu1jDdKMNz2vwJe7gNS_L6BXNTks4Fx1AHiJitKBBeCY95X-uIfeh03KdTtquI96Xsp8b1a6hGUDy7Wf802VM0FpnVsQruqXu-USTHnBO4wMsFqW6XaVqn2VVb-_M81D_h3dxW82oGVD1bf-v-Mg2rA6XtNCWFUsJ8Tfa91</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2158188990</pqid></control><display><type>article</type><title>Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Banach, Maciej ; Horzelski, Wojciech ; Oszukowski, Przemysław ; Suliburska, Joanna ; Kocyłowski, Rafał ; Gaj, Zuzanna ; Grzesiak, Mariusz ; von Kaisenberg, C.</creator><contributor>Giustarini, Daniela ; Daniela Giustarini</contributor><creatorcontrib>Banach, Maciej ; Horzelski, Wojciech ; Oszukowski, Przemysław ; Suliburska, Joanna ; Kocyłowski, Rafał ; Gaj, Zuzanna ; Grzesiak, Mariusz ; von Kaisenberg, C. ; Giustarini, Daniela ; Daniela Giustarini</creatorcontrib><description>Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administration of the tocolytic drug Atosiban—a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm birth and its impact on the level of oxidative stress in pregnant women after 48 hours of tocolytic treatment. This prospective study was conducted between March 2016 and August 2017 at the Obstetric Clinic of the Polish Mother’s Memorial Hospital Research Institute. Total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl, and thiol group levels were measured using an ELISA test in serum and plasma of 56 pregnant women before and after 48 hours of continuous administration of Atosiban. We found that TAS levels decreased almost twice after the 48-hour drug administration (0.936 ± 0.360 mmol/L vs. 0.582 ± 0.305 mmol/L, P&lt;0.001) while TOS increased from 18.217 ± 16.093 μmol/L to 30.442 ± 30.578 μmol/L (P&lt;0.001). We also found a significant increase in OSI index—almost a threefold increase from 0.022 ± 0.022 to 0.075 ± 0.085, P&lt;0.001. In addition, statistically significant differences in the level of carbonyl groups were found. It increased from 65.358 ± 31.332 μmol/L to 97.982 ± 38.047 μmol/L (P&lt;0.001), which indicates increased oxidation of plasma proteins. Furthermore, patients who gave birth prematurely had higher levels of TOS after a 48-hour drug administration than the second group with labor after 37 weeks of pregnancy (42.803 ± 34.683 μmol/L vs. 25.792 ± 27.821 μmol/L, P&lt;0.031). The obtained results clearly indicate that pregnant women during tocolytic treatment with Atosiban are in a state of increased oxidative stress and occurrence of preterm birth can be associated with this phenomenon. This trial is registered with NCT03570294.</description><identifier>ISSN: 1942-0900</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2018/3919106</identifier><identifier>PMID: 30622667</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Analysis ; Antioxidants ; Biomarkers ; Blood proteins ; Clinical Study ; Drug dosages ; Endocrinology ; Enzyme-linked immunosorbent assay ; Ethylenediaminetetraacetic acid ; Gynecology ; Hospitals ; Infants (Premature) ; Mortality ; Obstetrics ; Oxidative stress ; Poland ; Pregnancy ; Pregnancy complications ; Pregnant women ; Premature birth ; Proteins ; Womens health</subject><ispartof>Oxidative medicine and cellular longevity, 2018-01, Vol.2018 (2018), p.1-8</ispartof><rights>Copyright © 2018 Mariusz Grzesiak et al.</rights><rights>COPYRIGHT 2018 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2018 Mariusz Grzesiak et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2018 Mariusz Grzesiak et al. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663</citedby><cites>FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663</cites><orcidid>0000-0001-6690-6874 ; 0000-0003-0306-0239 ; 0000-0001-5554-1937 ; 0000-0002-1803-1935 ; 0000-0002-6900-4347 ; 0000-0002-0937-8427 ; 0000-0002-3690-5368 ; 0000-0003-4094-7103</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2158188990/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2158188990?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30622667$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Giustarini, Daniela</contributor><contributor>Daniela Giustarini</contributor><creatorcontrib>Banach, Maciej</creatorcontrib><creatorcontrib>Horzelski, Wojciech</creatorcontrib><creatorcontrib>Oszukowski, Przemysław</creatorcontrib><creatorcontrib>Suliburska, Joanna</creatorcontrib><creatorcontrib>Kocyłowski, Rafał</creatorcontrib><creatorcontrib>Gaj, Zuzanna</creatorcontrib><creatorcontrib>Grzesiak, Mariusz</creatorcontrib><creatorcontrib>von Kaisenberg, C.</creatorcontrib><title>Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administration of the tocolytic drug Atosiban—a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm birth and its impact on the level of oxidative stress in pregnant women after 48 hours of tocolytic treatment. This prospective study was conducted between March 2016 and August 2017 at the Obstetric Clinic of the Polish Mother’s Memorial Hospital Research Institute. Total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl, and thiol group levels were measured using an ELISA test in serum and plasma of 56 pregnant women before and after 48 hours of continuous administration of Atosiban. We found that TAS levels decreased almost twice after the 48-hour drug administration (0.936 ± 0.360 mmol/L vs. 0.582 ± 0.305 mmol/L, P&lt;0.001) while TOS increased from 18.217 ± 16.093 μmol/L to 30.442 ± 30.578 μmol/L (P&lt;0.001). We also found a significant increase in OSI index—almost a threefold increase from 0.022 ± 0.022 to 0.075 ± 0.085, P&lt;0.001. In addition, statistically significant differences in the level of carbonyl groups were found. It increased from 65.358 ± 31.332 μmol/L to 97.982 ± 38.047 μmol/L (P&lt;0.001), which indicates increased oxidation of plasma proteins. Furthermore, patients who gave birth prematurely had higher levels of TOS after a 48-hour drug administration than the second group with labor after 37 weeks of pregnancy (42.803 ± 34.683 μmol/L vs. 25.792 ± 27.821 μmol/L, P&lt;0.031). The obtained results clearly indicate that pregnant women during tocolytic treatment with Atosiban are in a state of increased oxidative stress and occurrence of preterm birth can be associated with this phenomenon. This trial is registered with NCT03570294.</description><subject>Analysis</subject><subject>Antioxidants</subject><subject>Biomarkers</subject><subject>Blood proteins</subject><subject>Clinical Study</subject><subject>Drug dosages</subject><subject>Endocrinology</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Gynecology</subject><subject>Hospitals</subject><subject>Infants (Premature)</subject><subject>Mortality</subject><subject>Obstetrics</subject><subject>Oxidative stress</subject><subject>Poland</subject><subject>Pregnancy</subject><subject>Pregnancy complications</subject><subject>Pregnant women</subject><subject>Premature birth</subject><subject>Proteins</subject><subject>Womens health</subject><issn>1942-0900</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqN0c1rFDEYBvBBFPuhN88S8CLo2nxMMpOLsBY_ioUKLngMmeTNbspMsibZ1v73Zt11q548JZAfT96Xp2meEfyGEM7PKCb9GZNEEiweNMdEtnSGpWwfHu4YHzUnOV9jLBhtyePmiGFBqRDdcfP56oe3uvgbQF9LgpyRD-hbnCCgRQJdwKJbX1ZoXmL2gw7IxYQupjUE68MSfUlQIE3onU9l9aR55PSY4en-PG0WH94vzj_NLq8-XpzPL2emlbLMGOuAuIGYlgvcOcMH1zLGbScGzcDaFozrpeaWG9CG2A7awQkiATrSCcFOm7e72PVmmMAaCCXpUa2Tn3S6U1F79fdL8Cu1jDdKMNz2vwJe7gNS_L6BXNTks4Fx1AHiJitKBBeCY95X-uIfeh03KdTtquI96Xsp8b1a6hGUDy7Wf802VM0FpnVsQruqXu-USTHnBO4wMsFqW6XaVqn2VVb-_M81D_h3dxW82oGVD1bf-v-Mg2rA6XtNCWFUsJ8Tfa91</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Banach, Maciej</creator><creator>Horzelski, Wojciech</creator><creator>Oszukowski, Przemysław</creator><creator>Suliburska, Joanna</creator><creator>Kocyłowski, Rafał</creator><creator>Gaj, Zuzanna</creator><creator>Grzesiak, Mariusz</creator><creator>von Kaisenberg, C.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6690-6874</orcidid><orcidid>https://orcid.org/0000-0003-0306-0239</orcidid><orcidid>https://orcid.org/0000-0001-5554-1937</orcidid><orcidid>https://orcid.org/0000-0002-1803-1935</orcidid><orcidid>https://orcid.org/0000-0002-6900-4347</orcidid><orcidid>https://orcid.org/0000-0002-0937-8427</orcidid><orcidid>https://orcid.org/0000-0002-3690-5368</orcidid><orcidid>https://orcid.org/0000-0003-4094-7103</orcidid></search><sort><creationdate>20180101</creationdate><title>Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth</title><author>Banach, Maciej ; Horzelski, Wojciech ; Oszukowski, Przemysław ; Suliburska, Joanna ; Kocyłowski, Rafał ; Gaj, Zuzanna ; Grzesiak, Mariusz ; von Kaisenberg, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Analysis</topic><topic>Antioxidants</topic><topic>Biomarkers</topic><topic>Blood proteins</topic><topic>Clinical Study</topic><topic>Drug dosages</topic><topic>Endocrinology</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Gynecology</topic><topic>Hospitals</topic><topic>Infants (Premature)</topic><topic>Mortality</topic><topic>Obstetrics</topic><topic>Oxidative stress</topic><topic>Poland</topic><topic>Pregnancy</topic><topic>Pregnancy complications</topic><topic>Pregnant women</topic><topic>Premature birth</topic><topic>Proteins</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banach, Maciej</creatorcontrib><creatorcontrib>Horzelski, Wojciech</creatorcontrib><creatorcontrib>Oszukowski, Przemysław</creatorcontrib><creatorcontrib>Suliburska, Joanna</creatorcontrib><creatorcontrib>Kocyłowski, Rafał</creatorcontrib><creatorcontrib>Gaj, Zuzanna</creatorcontrib><creatorcontrib>Grzesiak, Mariusz</creatorcontrib><creatorcontrib>von Kaisenberg, C.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Banach, Maciej</au><au>Horzelski, Wojciech</au><au>Oszukowski, Przemysław</au><au>Suliburska, Joanna</au><au>Kocyłowski, Rafał</au><au>Gaj, Zuzanna</au><au>Grzesiak, Mariusz</au><au>von Kaisenberg, C.</au><au>Giustarini, Daniela</au><au>Daniela Giustarini</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>2018</volume><issue>2018</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>1942-0900</issn><eissn>1942-0994</eissn><abstract>Preterm birth is defined as delivery before 37 completed weeks of pregnancy, and it is the leading cause of neonatal morbidity and mortality. Oxidative stress is recognized as an important factor in the pathogenesis of premature labor. We conducted this analysis to investigate the safety of administration of the tocolytic drug Atosiban—a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm birth and its impact on the level of oxidative stress in pregnant women after 48 hours of tocolytic treatment. This prospective study was conducted between March 2016 and August 2017 at the Obstetric Clinic of the Polish Mother’s Memorial Hospital Research Institute. Total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl, and thiol group levels were measured using an ELISA test in serum and plasma of 56 pregnant women before and after 48 hours of continuous administration of Atosiban. We found that TAS levels decreased almost twice after the 48-hour drug administration (0.936 ± 0.360 mmol/L vs. 0.582 ± 0.305 mmol/L, P&lt;0.001) while TOS increased from 18.217 ± 16.093 μmol/L to 30.442 ± 30.578 μmol/L (P&lt;0.001). We also found a significant increase in OSI index—almost a threefold increase from 0.022 ± 0.022 to 0.075 ± 0.085, P&lt;0.001. In addition, statistically significant differences in the level of carbonyl groups were found. It increased from 65.358 ± 31.332 μmol/L to 97.982 ± 38.047 μmol/L (P&lt;0.001), which indicates increased oxidation of plasma proteins. Furthermore, patients who gave birth prematurely had higher levels of TOS after a 48-hour drug administration than the second group with labor after 37 weeks of pregnancy (42.803 ± 34.683 μmol/L vs. 25.792 ± 27.821 μmol/L, P&lt;0.031). The obtained results clearly indicate that pregnant women during tocolytic treatment with Atosiban are in a state of increased oxidative stress and occurrence of preterm birth can be associated with this phenomenon. This trial is registered with NCT03570294.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>30622667</pmid><doi>10.1155/2018/3919106</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6690-6874</orcidid><orcidid>https://orcid.org/0000-0003-0306-0239</orcidid><orcidid>https://orcid.org/0000-0001-5554-1937</orcidid><orcidid>https://orcid.org/0000-0002-1803-1935</orcidid><orcidid>https://orcid.org/0000-0002-6900-4347</orcidid><orcidid>https://orcid.org/0000-0002-0937-8427</orcidid><orcidid>https://orcid.org/0000-0002-3690-5368</orcidid><orcidid>https://orcid.org/0000-0003-4094-7103</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1942-0900
ispartof Oxidative medicine and cellular longevity, 2018-01, Vol.2018 (2018), p.1-8
issn 1942-0900
1942-0994
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6304866
source Wiley Online Library Open Access; Publicly Available Content Database
subjects Analysis
Antioxidants
Biomarkers
Blood proteins
Clinical Study
Drug dosages
Endocrinology
Enzyme-linked immunosorbent assay
Ethylenediaminetetraacetic acid
Gynecology
Hospitals
Infants (Premature)
Mortality
Obstetrics
Oxidative stress
Poland
Pregnancy
Pregnancy complications
Pregnant women
Premature birth
Proteins
Womens health
title Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A23%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxidative%20Stress%20in%20Women%20Treated%20with%20Atosiban%20for%20Impending%20Preterm%20Birth&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Banach,%20Maciej&rft.date=2018-01-01&rft.volume=2018&rft.issue=2018&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2018/3919106&rft_dat=%3Cgale_pubme%3EA602717127%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-337e1fb1c45607fc5bf4335d76ba3edd4ecf89a5d5ceac1d7e4bf619ee717663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2158188990&rft_id=info:pmid/30622667&rft_galeid=A602717127&rfr_iscdi=true